In addressing the issue‚ the following were considered: a sensitivity analysis for potential consumption of different price series‚ associated revenues and costs‚ and gross profit from different distribution methods. It is recommended that Biopure: 1. Introduce Oxyglobin immediately at a price of $100 to veterinarians. 2. Have an independent sales force distribute the product to maximize profits. 3. Advertise Oxyglobin in both veterinarian journals and trade shows. 4. Establish
Premium Blood Blood transfusion Red blood cell
in its ability to market its blood substitute technology for both animal and human use. Further‚ Biopure has the patents and FDA approval to forge ahead in the animal market with a two-to-five year time buffer from new competition (using similar technology). One of the company’s weaknesses is that it has not received FDA approval on Hemopure‚ and there are two other companies that could beat Biopure to the market with similar products. But if the FDA does not approve Hemopure‚ which could have
Premium Blood Pharmacology Marketing
oxygen requirements in a broad range of potential medical applications. The main issue that is plaguing Biopure is how the possible launch of Oxyglobin will affect the future launch and pricing strategies of Hemopure‚ which could provide a larger return for their investment. Biopure’s strength lies in their ability to market its blood substitute products for both human and animal use. Biopure has a product that has been approved by the FDA for animal use and has the intellectual property that will
Premium Blood Marketing Blood transfusion
MAC Development Corporation The McCaffreys are in a sticky situation as they have tied up land for a development project and everything seems to be falling apart. They have deadlines to meet and so many moving pieces that I had to read the Case Study several times to wrap my head around it all. At the start of the Phoenix project‚ there were basically three main puzzle pieces the McCaffreys had to juggle. The first one was the Village of Woodland‚ where the land was located‚ had verbally
Premium September 11 attacks Investment Risk
Case: Land Securities Group (A): Choosing Cost or Fair Value on Adoption of IFRS Case Number: 9-105-014 Topic: Financial Reporting and Control Description: A U.K. real estate firm‚ required to adopt international accounting standards (IAS) by 2005‚ must change the reporting of its primary asset (investment property) from the revaluation model under U.K. GAAP to either the cost or fair-value model under IAS. This would have a number of effects on European investment property firms‚ including
Premium Financial statements International Financial Reporting Standards Finance
veterinarians and trade fair attracted 2‚000 to 10‚000 veterinarian each. In additional to all the strategies above‚ we recommend BioPure to launch campaign “Love Me Love My Pet” in order to increase awareness to people and encourage them to save pet’s life like our own. For people not to differentiate human life and animal life but rather think of it in the same aspect. BioPure should joint this campaign with non-profit organizer and government in order to emphasize the important of the issue publicly
Free Blood
Biopure Overview: * Biopure Corporation is a privately owned biopharmaceutical firm specializing in the ultrapurification of proteins for human and veterinary use. * It is one of the three legitimate contenders in the emerging field of “blood substitutes”. * Their products Oxyglobin and Hemopure are blood substitutes for the animal and the human market respectively. * Oxyglobin has just received final FDA approval for commercial release and is ready for launch. Hemopure would soon
Premium Blood Blood transfusion
Biopure Corporation Written Case Study I. Current Situation Audit A. Issue Oxyglobin and Hemopure are two blood substitutes that Biopure Corporation was developing. Oxyglobin was recently approved by the FDA for veterinary use while Hemapure is estimated to be approved in two years for human use. If Oxyglobin is launched it will be the first blood substitute for the veterinary market a small and price sensitive market. There is a perceived risk by Ted Jacobs‚ the VP of Human Clinical Trials
Free Blood Blood transfusion
Biopure Case Analysis Group 1‚ Section B The analysis deals with the Target Markets and their different segments for the two products of Biopure Corporation‚ namely Oxyglobin and Hemopure. Oxyglobin -‐ Used as a substitute for blood transfusion in dogs. -‐ Target market is 30% of all the
Premium
How best to exploit the opportunity presented by Oxyglobin without jeopardizing the potential of Hemopure is a tough problem for Biopure’s executive. According to the financial analysis‚ it is suggested that Biopure begin to sell Oxyglobin at $150 per unit to emergency care practice at the Veterinary Blood Market and have its own distribution network. This will make a profit of $5 million at first year and $17 million thereafter. The steadfast income will consolidate Biopure’s financial structure
Premium Blood Marketing Economics